Concomitant use of triptan, and SSRI or SNRI after the US food and drug administration alert on serotonin syndrome

Headache

Volumn 52, Issue 2, 2012, Pages 198-203

  Sclar, David A ^a,b   Robison, Linda M ^a   Castillo, Leigh V ^a   Schmidt, Jennifer M ^a   Bowen, Kurt A ^a   Oganov, Ambartsum M ^a   Skaer, Tracy L ^a   Kogut, Stephen J ^c  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Washington Institute for Mental Illness Research and Training   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

5 hydroxytryptamine receptor agonist; drug drug interaction; selective serotonin reuptake inhibitor; serotonin syndrome; serotonin norepinephrine reuptake inhibitor; US National Ambulatory Medical Care Survey

Indexed keywords

ALMOTRIPTAN; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ELETRIPTAN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FROVATRIPTAN; NARATRIPTAN; PAROXETINE; RIZATRIPTAN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TRIPTAN DERIVATIVE; VENLAFAXINE; ZOLMITRIPTAN;

ADULT; ARTICLE; DRUG UTILIZATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SEROTONIN SYNDROME; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; RISK; SEROTONIN RECEPTOR AGONISTS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; TRYPTAMINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84857057681     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.02067.x     Document Type: Article

References (25)

1. Lipton RB, Bigal ME, Diamond M, et al,. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343-349. (Pubitemid 46184209)
2. Silberstein S, Loder E, Diamond S, et al,. Probable migraine in the United States: Results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia. 2007; 27: 220-234.
3. Hamelsky SW, Lipton RB,. Psychiatric comorbidity of migraine. Headache. 2006; 46: 1327-1333. (Pubitemid 44556425)
4. Evans RW, Rosen N,. Migraine, psychiatric comorbidities, and treatment. Headache. 2008; 48: 952-958. (Pubitemid 351792737)
5. Shapiro RE, Tepper SJ,. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007; 47: 266-269.
6. Stovner LJ, Hagen K, Jensen R, et al,. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27: 193-210. (Pubitemid 46354128)
7. FDA Alert. Combined Use of 5-Hydroxytryptamine Receptor Agonists (Triptans), Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) May Result in Life-threatening Serotonin Syndrome. July, 2006. Available at: (accessed October 1, 2011).
8. US Food and Drug Administration. Meridia (sibutramine hydrochloride monohydrate) 5, 10, and 15 mg Capsules. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). May, 2009. Available at: (accessed October 1, 2011).
9. Evans CE, Sebastian J,. Serotonin syndrome. Emerg Med J. 2007; 24: e20.
10. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB,. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache. 2007; 47: 355-363. (Pubitemid 46426410)
11. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE,. The FDA Alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitor (SSRI) or a selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010; 50: 1089-1099.
12. Sclar DA, Robison LM, Skaer TL,. Concomitant triptan and SSRI or SNRI use: A risk for serotonin syndrome. Headache. 2008; 48: 126-129.
13. National Center for Health Statistics. National Ambulatory Medical Care Surveys, 2007-2008. Microdata available at.
14. Bryant E, Shimizu I,. Sampling design, sampling variance, and estimation procedures for the National Ambulatory Medical Care Survey. National Center for Health Statistics. Vital Health Stat 2. 1988; 108: 1-39.
15. U.S. Public Health Service and Health Care Financing Administration. International Classification of Diseases. 9th Revision, Clinical Modification, Volume 1. DHHS publication no.(PHS) 89-1260. Washington, DC: Public Health Service; 1989.
16. Food and Drug Administration. National Drug Code Directory, 1995 edn. Washington, DC: Public Health Service; 1995.
17. Koch H, Campbell W,. The collection and processing of drug information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat. 1982; 2: 1-90.
18. Cerner Multum, Inc. 2005., (accessed October 1, 2011).
19. Sclar DA, Robison LM, Skaer TL, Galin RS,. Ethnicity and the prescribing of antidepressant pharmacotherapy: 1992-1995. Harv Rev Psychiatry. 1999; 7: 29-36. (Pubitemid 29426050)
20. Skaer TL, Sclar DA, Robison LM, Galin RS,. Trend in the use of antidepressant pharmacotherapy and diagnosis of depression in the US: An assessment of office-based visits 1990 to 1998. CNS Drugs. 2000; 14: 473-481. (Pubitemid 32042677)
21. Robison LM, Skaer TL, Sclar DA, Galin RS,. Is attention-deficit/ hyperactivity disorder increasing among girls in the U.S.? Trends in diagnosis and the prescribing of stimulants. CNS Drugs. 2002; 16: 129-137. (Pubitemid 34155209)
22. Sclar DA, Robison LM, Skaer TL,. Ethnicity/race and the diagnosis of depression and use of antidepressants by adults in the United States. Int Clin Psychopharmacol. 2008; 23: 106-109. (Pubitemid 351317283)
23. Skaer TL, Sclar DA, Robison LM,. Trends in prescriptions for antidepressant pharmacotherapy among U.S. children and adolescents diagnosed with depression: An assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. Clin Ther. 2009; 31: 1478-1487.
24. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S,. Coprescription of triptans with potentially interacting medications: A cohort study involving 240,268 patients. Headache. 2003; 43: 44-48. (Pubitemid 36150989)
25. Kogut SJ,. Do triptan antimigraine medications interact with SSRI/SNRI antidepressants? What does your decision support system say? J Manag Care Pharm. 2011; 17: 547-551.